1. Lazzarini PA, Gurr JM, Rogers JR, Schox A, Bergin SM. Australia's 'silent pandemic'of diabetes complications: where do feet stand in this pandemic?. Journal of Foot and Ankle Research. 2013 ;6(1):1. [
DOI:10.1186/1757-1146-6-1]
2. Prabhakar PK. Pathophysiology of secondary complications of diabetes mellitus. Pathophysiology. 2016;9(1).
3. Uppal V, Vij C, Bedi GK, Vij A, Banerjee BD. Thyroid disorders in patients of type 2 diabetes mellitus. Indian Journal of Clinical Biochemistry. 2013 ;28(4):336-41. [
DOI:10.1007/s12291-012-0293-9]
4. Elgazar EH, Esheba NE, Shalaby SA, Mohamed WF. Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019 ;13(4):2513-7. [
DOI:10.1016/j.dsx.2019.07.020]
5. Pasupathi P, Bakthavathsalam G, Saravanan G, Sundaramoorthi R. Screening for thyroid dysfunction in the diabetic/non-diabetic population. Thyroid Science. 2008;3(8):1-6.
6. Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocrine reviews. 2019 ;40(3):789-824. [
DOI:10.1210/er.2018-00163]
7. Rai S, KUMAR JA, Prajna K, Shetty SK, Rai T, Begum M. Thyroid function in type 2 diabetes mellitus and in diabetic nephropathy. Journal of Clinical & Diagnostic Research. 2013 ;7(8):1583.
8. Elebrashy IN, El Meligi A, Rashed L, Salam RF, Youssef E, Fathy SA. Thyroid dysfunction among type 2 diabetic female Egyptian subjects. Therapeutics and Clinical Risk Management. 2016;12:1757. [
DOI:10.2147/TCRM.S112302]
9. Valdes S, Maldonado-Araque C, Lago-Sampedro A, Lillo JA, Garcia-Fuentes E, Perez-Valero V, et al. Population-based national prevalence of thyroid dysfunction in Spain and associated factors: Di@ bet. es Study. Thyroid. 2017 ;27(2):156-66. [
DOI:10.1089/thy.2016.0353]
10. Gibson DM. Reversible Phosphorylation of Hepatic HMG-CoA Reductase in Endocrine and Feedback Control of Cholesterol Biosynthesis. In: Preiss B, editor. Regulation of HMG-CoA reductase. Elsevier; 2012.
11. Elmenshawi I, Alotaibi S, Alazmi A, Alazmi A, Alruwaili F, Alazmi N, et al. Prevalence of thyroid dysfunction in diabetic patients. Journal of Diabetes Metabolic Disorders & Control. 2017;4:55-6. [
DOI:10.15406/jdmdc.2017.04.00106]
12. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction?. Journal of Thyroid Research. 2011 ;2011. [
DOI:10.4061/2011/152850]
13. De Vito P, Candelotti E, G Ahmed R, Luly P, J Davis P, Incerpi S, et al. Role of thyroid hormones in insulin resistance and diabetes. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Immunology, Endocrine and Metabolic Agents). 2015 ;15(1):86-93. [
DOI:10.2174/187152221501150710132153]
14. Guptha S, Gupta R, Deedwania P, Bhansali A, Maheshwari A, Gupta A, et al. Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study. indian heart journal. 2014 ;66(3):280-8. [
DOI:10.1016/j.ihj.2014.03.005]
15. Peppa M, Betsi G, Dimitriadis G. Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease. Journal of lipids. 2011 ;2011. [
DOI:10.1155/2011/575840]
16. Liu XL, He S, Zhang SF, Wang J, Sun XF, Gong CM, et al. Alteration of lipid profile in subclinical hypothyroidism: a meta-analysis. Medical science monitor: international medical journal of experimental and clinical research. 2014;20:1432. [
DOI:10.12659/MSM.891163]
17. Vitale G, Salvioli S, Franceschi C. Oxidative stress and the ageing endocrine system. Nature Reviews Endocrinology. 2013 ;9(4):228-40. [
DOI:10.1038/nrendo.2013.29]
18. Abreu IM, Lau E, de Sousa Pinto B, Carvalho D. Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocrine connections. 2017 ;6(3):188-99. [
DOI:10.1530/EC-17-0028]